Romiplostim for low platelets from chemo in kids
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a drug called romiplostim to help raise platelet levels in children and young adults (ages 6–24) whose platelets drop due to chemotherapy. It’s for those with solid tumors or other non-marrow cancers who are still getting strong treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 6 to 24 years old.
- You must have a type of cancer that is not in the bone marrow (like leukemia) and be getting strong chemotherapy.
- Your platelet count must be below 75,000 due to chemotherapy.
- You must be able to receive at least 2 more chemotherapy cycles.
- You cannot have other causes of low platelets, other blood disorders, or recent blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
This study tests a new medication called romiplostim that may help raise your platelet count when it drops too low after radiation therapy. If you have a solid tumor and your platelets are below 75,000, this treatment could help you recover and avoid complications.
This trial tests a platelet-boosting medicine called romiplostim to prevent dangerously low platelet counts caused by chemotherapy in children with newly diagnosed Ewing sarcoma. It is designed for patients who do not have cancer spread to the bone marrow and have not taken similar platelet drugs before.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
Hear when a new Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.